RXRX · Company research
Recursion Pharmaceuticals, Inc. (RXRX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
25records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| RXRX Stock Pops As Sanofi Deal And ARK Buying Fuel AI-Drug Hype - Timothy Sykes | RXRX Stock Pops As Sanofi Deal And ARK Buying Fuel AI-Drug Hype Timothy Sykes | View source ↗ | Timothy Sykes | Oct 19, 2026 | neutral | 0 | 0.6 |
| RXRX Stock Pops As Sanofi Deal, ARK Buying Fuel AI Biotech Story - Timothy Sykes | RXRX Stock Pops As Sanofi Deal, ARK Buying Fuel AI Biotech Story Timothy Sykes | View source ↗ | Timothy Sykes | Oct 19, 2026 | neutral | 0 | 0.6 |
| Has Recursion Pharmaceuticals (RXRX) Fallen Far Enough on Sales? - Yahoo Finance | Has Recursion Pharmaceuticals (RXRX) Fallen Far Enough on Sales? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 19, 2026 | neutral | 0 | 0.6 |
| Recursion Pharmaceuticals (RXRX) Stock Sees Modest Fair Value Lift After Analyst Target Revisions - Yahoo Finance | Recursion Pharmaceuticals (RXRX) Stock Sees Modest Fair Value Lift After Analyst Target Revisions Yahoo Finance | View source ↗ | Yahoo Finance | Oct 19, 2026 | neutral | 0 | 0.6 |
| Recursion Pharmaceuticals Stock Price Forecast. Should You Buy RXRX? - StockInvest.us | Recursion Pharmaceuticals Stock Price Forecast. Should You Buy RXRX? StockInvest.us | View source ↗ | StockInvest.us | Oct 16, 2026 | neutral | 0 | 0.6 |
| Recursion Pharmaceuticals (RXRX) Institutional Ownership 2026 $RXRX - MarketBeat | Recursion Pharmaceuticals (RXRX) Institutional Ownership 2026 $RXRX MarketBeat | View source ↗ | MarketBeat | Oct 16, 2026 | neutral | 0 | 0.6 |
| Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here’s What You Should Know - TradingView | Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here’s What You Should Know TradingView | View source ↗ | TradingView | Oct 16, 2026 | neutral | 0 | 0.6 |
| RXRX Stock Heads For Its Best Day In Over A Year – What’s Driving The Rally Today? - Stocktwits | RXRX Stock Heads For Its Best Day In Over A Year – What’s Driving The Rally Today? Stocktwits | View source ↗ | Stocktwits | Oct 15, 2026 | neutral | 0 | 0.6 |
| RXRX Stock Draws ARK Buying As AI Deals Deepen - StocksToTrade | RXRX Stock Draws ARK Buying As AI Deals Deepen StocksToTrade | View source ↗ | StocksToTrade | Oct 15, 2026 | neutral | 0 | 0.6 |
| Two patients had at least 98% fewer polyps in the upper digestive tract - Stock Titan | Two patients had at least 98% fewer polyps in the upper digestive tract Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note | Recursion Pharmaceuticals (RXRX) fell 8.03% in the latest trading session, significantly underperforming the S&P 500's 0.06% decline. Despite a 36.25% gain over the past month, the stock has received a Zacks Rank #4 (Sell) rating. The company faces headwinds with consensus EPS estimates revised 2.17% lower over the past month, though revenue projections show growth. The biotech sector itself ranks in the bottom 33% of industries. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bearish | -1 | 1 |
| RXRX Stock Drifts Lower As Traders Gauge Biotech Runway - StocksToTrade | RXRX Stock Drifts Lower As Traders Gauge Biotech Runway StocksToTrade | View source ↗ | StocksToTrade | Oct 12, 2026 | neutral | 0 | 0.6 |
| Tempus AI Expands Strategic Collaborations to Drive Future Growth | Tempus AI (TEM) is strengthening its precision medicine presence through multiple strategic collaborations, including support for Moderna and Merck's cancer therapy commercialization and an extended data partnership with Recursion Pharmaceuticals through 2029. However, TEM's stock has underperformed the industry by 30.6% over the past year and trades at a premium valuation of 6.73X forward P/S versus the industry average of 4.90X, with the stock currently rated a Hold. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bullish | 0.833 | 1 |
| RXRX Stock Dips As Traders Weigh Cash Runway And Heavy Losses - Timothy Sykes | RXRX Stock Dips As Traders Weigh Cash Runway And Heavy Losses Timothy Sykes | View source ↗ | Timothy Sykes | Oct 8, 2026 | neutral | 0 | 0.6 |
| Under a trading plan, Recursion (RXRX) director sells 50,000 shares averaging $4.84 each. - Stock Titan | Under a trading plan, Recursion (RXRX) director sells 50,000 shares averaging $4.84 each. Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| A director sells 25,000 shares at $5 after exercising options at $2.22 at Recursion (RXRX). - Stock Titan | A director sells 25,000 shares at $5 after exercising options at $2.22 at Recursion (RXRX). Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors | Recursion Pharmaceuticals (RXRX) declined 3.14% to $4.63 on October 6, 2026, underperforming the broader market which gained modestly. Despite a strong 31.68% monthly gain, the stock fell as the S&P 500 rose 0.58%. The company is expected to report an EPS of -$0.24 with revenue of $8.42 million, showing improvement year-over-year. RXRX holds a Zacks Rank #3 (Hold) rating with recent downward EPS estimate revisions. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | neutral | 0 | 1 |
| Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance | Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors Yahoo Finance | View source ↗ | Yahoo Finance | Oct 6, 2026 | neutral | 0 | 0.6 |
| Recursion Pharmaceuticals Shares Jump as AI Partnership Momentum and Short-Covering Appear to Lift Sentiment - Quiver Quantitative | Recursion Pharmaceuticals Shares Jump as AI Partnership Momentum and Short-Covering Appear to Lift Sentiment Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 5, 2026 | neutral | 0 | 0.6 |
| RXRX Rises As Tempus AI Deal Locks In $42M - Timothy Sykes | RXRX Rises As Tempus AI Deal Locks In $42M Timothy Sykes | View source ↗ | Timothy Sykes | Oct 5, 2026 | neutral | 0 | 0.6 |
| Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? - TradingView | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? TradingView | View source ↗ | TradingView | Sep 24, 2026 | neutral | 0 | 0.6 |
| Recursion Pharmaceuticals (RXRX) Stock Moves 2.02%: What You Should Know - Yahoo Finance | Recursion Pharmaceuticals (RXRX) Stock Moves 2.02%: What You Should Know Yahoo Finance | View source ↗ | Yahoo Finance | Sep 22, 2026 | neutral | 0 | 0.6 |
| Is Recursion Pharmaceuticals (RXRX) A Bargain As Its Shares Rebound? - Yahoo Finance | Is Recursion Pharmaceuticals (RXRX) A Bargain As Its Shares Rebound? Yahoo Finance | View source ↗ | Yahoo Finance | Sep 19, 2026 | neutral | 0 | 0.6 |
| Recursion Pharmaceuticals Stock (RXRX) Opinions on Pipeline Catalysts Amid Earnings Concerns - Quiver Quantitative | Recursion Pharmaceuticals Stock (RXRX) Opinions on Pipeline Catalysts Amid Earnings Concerns Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 25, 2026 | neutral | 0 | 0.6 |
| RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits | RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ Stocktwits | View source ↗ | Stocktwits | Mar 5, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.